Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006324 · ClinicalTrials.gov registry record · NA

Hormonal Birth Control and the Risk of Acquiring HIV

A NA study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
NA
Development phase
6,360
Enrollment target

NCT00006324: Completed NA study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

NCT00006324 is a NA study that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 6,360 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (353% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006324, a NA study, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
NA
Development phase
6,360 participants
Enrollment target

Study Summary

The purpose of this study is to find out whether hormonal birth control increases, decreases, or does not change the risk of women becoming infected with HIV. Sexual intercourse between men and women is the main way HIV is transmitted. About 90 percent of HIV infections in women are caused by sexual intercourse. Also, hormonal birth controls are widely used. This study hopes to find out whether hormonal birth control changes the risk of women becoming infected with HIV.

Interventions

  • DRUG Medroxyprogesterone acetate
  • DRUG Ethinyl estradiol/levonorgestrel

Trial Details

FieldValue
Enrollment Target 6,360 participants
Start Date 1999-12
Est. Completion 2002-12
Phase NA

What the finished NCT00006324 record still lists

NCT00006324 is an interventional study that assigns participants to a tested intervention. Its 6,360 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (353% higher).

The record links to 0 conditions, and to 2 interventions - of which Medroxyprogesterone acetate is the first listed.

NCT00006324 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00006324 about?

NCT00006324 is a clinical study titled "Hormonal Birth Control and the Risk of Acquiring HIV". The purpose of this study is to find out whether hormonal birth control increases, decreases, or does not change the risk of women becoming infected with HIV. Sexual intercourse between men and women is the main way HIV is transmitted. About 90 percent of HIV infections in women are caused by sexua...

What is the current status of trial NCT00006324?

This trial is currently completed. It is a NA study. The enrollment target is 6,360 participants. The study started on 1999-12. Estimated completion is 2002-12.

What interventions are being tested in trial NCT00006324?

The interventions under investigation include: Medroxyprogesterone acetate (DRUG), Ethinyl estradiol/levonorgestrel (DRUG).

Who is sponsoring clinical trial NCT00006324?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00006324's enrollment target sits among peer trials

6,360 21st of 2000 higher than 1,980 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04884802 · 6,254 participants · NA

    The GUARDIAN Trial

  • NCT03960099 · 6,250 participants · NA

    Pictographs for Preventing Wrong-Patient Errors in NICUs

  • NCT05440851 · 6,250 participants · NA

    Platform of Randomized Adaptive Clinical Trials in Critical Illness

  • NCT06566170 · 6,250 participants

    A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00006324, the US trial registry maintained by the National Library of Medicine. NCT00006324 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.